Fibroblast Chemotaxis Induction by Human Recombinant Interleukin-4. Identification by Synthetic Peptide Analysis of Two Chemotactic Domains Residing in Amino Acid Sequences 70-88 and 89-122

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1991 Jun 1

PMID 2040697

Citations 21

Authors

A E Postlethwaite

J M Seyer

Affiliations

Soon will be listed here.

Abstract

Interleukin-4 is a T lymphocyte- and mast cell-derived cytokine with pleiotropic properties with biological effects on a variety of target cells including B and T lymphocytes, macrophages, hematopoietic cells, mast cells, and fibroblasts. In addition to the proliferation effect of IL-4 on fibroblasts, which has been previously described, in this report the chemotactic properties of IL-4 for fibroblasts is described. Human recombinant IL-4 induced the chemotactic migration of dermal fibroblasts in vitro in modified Boyden-type chambers at concentrations between 10(-12) and 10(-11) M. The chemotactic activity of IL-4 was neutralized by anti-human recombinant IL-4 IgG antibodies. Oligopeptides representing the complete deduced amino acid sequence of human IL-4 were synthesized by the Merrifield technique and tested for their ability to induce fibroblast chemotaxis. Two peptides representing residues 70-88 and 89-122 induced fibroblast migration. Peptide 70-88 was the more potent of the two causing chemotaxis of fibroblasts at 10(-8)-10(-6) M while peptide 89-129 induced migration at 10(-7)-10(-5) M. Although the mechanism by which IL-4 and these two peptides induce fibroblast chemotaxis is unknown, each of these three compounds were able to chemotactically desensitize fibroblasts to the chemotactic effects of the other two but not to a structurally unrelated chemotactic cytokine, transforming growth factor beta-1. These studies suggest that IL-4 might function in vivo to induce the accumulation of fibroblasts at sites of tissue injury, inflammatory and immune reactions in which T lymphocytes and mast cells participate.

Citing Articles

Four in one-Combination therapy using live Lactococcus lactis expressing three therapeutic proteins for the treatment of chronic non-healing wounds.

Kurkipuro J, Mierau I, Wirth T, Samaranayake H, Smith W, Karkkainen H PLoS One. 2022; 17(2):e0264775.

PMID: 35226700 PMC: 8884502. DOI: 10.1371/journal.pone.0264775.

A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis.

Wilgus T, Ud-Din S, Bayat A Int J Mol Sci. 2020; 21(24).

PMID: 33353063 PMC: 7766369. DOI: 10.3390/ijms21249673.

Chronic exposure of interleukin-13 suppress the induction of matrix metalloproteinase-1 by tumour necrosis factor α in normal and scleroderma dermal fibroblasts through protein kinase B/Akt.

Brown Lobbins M, Shivakumar B, Postlethwaite A, Hasty K Clin Exp Immunol. 2017; 191(1):84-95.

PMID: 28884475 PMC: 5721252. DOI: 10.1111/cei.13045.

Vascular involvement in systemic sclerosis (scleroderma).

Pattanaik D, Brown M, Postlethwaite A J Inflamm Res. 2011; 4:105-25.

PMID: 22096374 PMC: 3218751. DOI: 10.2147/JIR.S18145.

Pharmacotherapy of systemic sclerosis.

Postlethwaite A, Harris L, Raza S, Kodura S, Akhigbe T Expert Opin Pharmacother. 2010; 11(5):789-806.

PMID: 20210685 PMC: 2837533. DOI: 10.1517/14656561003592177.

References

Yokota T, Otsuka T, Mosmann T, Banchereau J, Defrance T, Blanchard D . Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. Proc Natl Acad Sci U S A. 1986; 83(16):5894-8. PMC: 386403. DOI: 10.1073/pnas.83.16.5894. View

Mosmann T, Bond M, Coffman R, OHara J, Paul W . T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc Natl Acad Sci U S A. 1986; 83(15):5654-8. PMC: 386347. DOI: 10.1073/pnas.83.15.5654. View

Antoni G, Presentini R, Perin F, Tagliabue A, Ghiara P, Censini S . A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J Immunol. 1986; 137(10):3201-4. View

Hu-Li J, Shevach E, Mizuguchi J, OHara J, Mosmann T, Paul W . B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J Exp Med. 1987; 165(1):157-72. PMC: 2188254. DOI: 10.1084/jem.165.1.157. View

Postlethwaite A, Keski-Oja J, Moses H, Kang A . Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med. 1987; 165(1):251-6. PMC: 2188256. DOI: 10.1084/jem.165.1.251. View

Crawford R, Finbloom D, OHara J, Paul W, Meltzer M . B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol. 1987; 139(1):135-41. View

Paul W, OHara J . B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol. 1987; 5:429-59. DOI: 10.1146/annurev.iy.05.040187.002241. View

Park L, Friend D, Sassenfeld H, Urdal D . Characterization of the human B cell stimulatory factor 1 receptor. J Exp Med. 1987; 166(2):476-88. PMC: 2189585. DOI: 10.1084/jem.166.2.476. View

Rennick D, Yang G, Smith C, Arai N, Takabe Y, Gemmell L . Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hemopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987; 84(19):6889-93. PMC: 299190. DOI: 10.1073/pnas.84.19.6889. View

10.

Lowenthal J, Castle B, Christiansen J, Schreurs J, Rennick D, Arai N . Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. J Immunol. 1988; 140(2):456-64. View

11.

Te Velde A, Klomp J, Yard B, De Vries J, Figdor C . Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol. 1988; 140(5):1548-54. View

12.

McInnes A, Rennick D . Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells. J Exp Med. 1988; 167(2):598-611. PMC: 2188835. DOI: 10.1084/jem.167.2.598. View

13.

Monroe J, Haldar S, Prystowsky M, Lammie P . Lymphokine regulation of inflammatory processes: interleukin-4 stimulates fibroblast proliferation. Clin Immunol Immunopathol. 1988; 49(2):292-8. DOI: 10.1016/0090-1229(88)90119-5. View

14.

Senior R, Griffin G, Perez H, Webster R . Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts. J Immunol. 1988; 141(10):3570-4. View

15.

Postlethwaite A, Smith Jr G, Lachman L, Endres R, Poppleton H, Hasty K . Stimulation of glycosaminoglycan synthesis in cultured human dermal fibroblasts by interleukin 1. Induction of hyaluronic acid synthesis by natural and recombinant interleukin 1s and synthetic interleukin 1 beta peptide 163-171. J Clin Invest. 1989; 83(2):629-36. PMC: 303724. DOI: 10.1172/JCI113927. View

16.

Essner R, Rhoades K, McBride W, Morton D, Economou J . IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol. 1989; 142(11):3857-61. View

17.

Postlethwaite A . Early immune events in scleroderma. Rheum Dis Clin North Am. 1990; 16(1):125-39. View

18.

Claman H . Mast cells and fibrosis. The relevance to scleroderma. Rheum Dis Clin North Am. 1990; 16(1):141-51. View

19.

Idzerda R, March C, Mosley B, Lyman S, Vanden Bos T, Gimpel S . Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med. 1990; 171(3):861-73. PMC: 2187789. DOI: 10.1084/jem.171.3.861. View

20.

Baum J . Source of the fibroblast in central corneal wound healing. Arch Ophthalmol. 1971; 85(4):473-7. DOI: 10.1001/archopht.1971.00990050475014. View